Drugs / IDE574
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07540572 | Mar 2026 → Mar 2030 expected | castration-resistant prostate carcinoma, colorectal carcinoma, estrogen-receptor positive breast cancer, non-small cell lung carcinoma | IDEAYA Biosciences | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDE574 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07540572 ↗ |
| Action | Inhibit | “small molecule inhibitor that co-targets” NCT07540572 ↗ |
| Modality | Small molecule | “IDE574 is a synthetically manufactured small molecule inhibitor” NCT07540572 ↗ |
| Target | KAT7 | “IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.” NCT07540572 ↗ |